Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article summarizes dermatologic adverse events in patients treated with afatinib in clinical trials and discusses strategies for managing these side effects, without providing new clinical results.

In this study using a macaque model, RU58841 at a 5% concentration significantly increased hair density, thickness, and length in the frontal bald scalp over six months.

Combining RU58841 and minoxidil significantly increases hair growth.

This review focuses on the immunologic-based skin conditions that can result from β-blocker use, emphasizing potential adverse dermatologic effects rather than their therapeutic benefits.

This report from the National Registry of Drug-Induced Ocular Side Effects identifies 56 cases of alopecia associated with the use of topical ophthalmic β-blockers.

Adding diltiazem to a beta blocker can cause dangerously slow heart rates.

This study found that combination therapy with alpha-adrenergic blockers and 5α-reductase inhibitors significantly improved urinary symptoms, reduced prostate volume, and decreased the risk of acute urinary retention and postoperative surgery in patients with benign prostatic hyperplasia compared to monotherapy.

This study outlines new strategies for overcoming "cold" tumors, which are typically unresponsive to cancer immunotherapy, with approaches like dendritic cell-based treatments and local immune microenvironment modification, bolstered by both preclinical and clinical trial data.

This study found that two novel nonsteroidal derivatives inhibited specific enzymes in vitro and in vivo, leading to dihydrotestosterone accumulation in androgen-dependent glands, suggesting potential therapeutic use for mood improvement in the elderly.

The source does not provide an abstract for this letter to the editor, so specific results regarding the long-term efficacy and safety of dutasteride for male androgenetic alopecia are not reported.

This study investigated the effects of YWS1903 in pregnant rats and found that high doses led to fetal growth reduction and skeletal malformations, while lower doses did not cause significant issues, establishing a no observed adverse effect level at 60 mg/kg.

This study found that cucurbitacin I from bitter melon most effectively inhibited the growth of lung cancer cells and promoted hair cell growth in cell cultures.

The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.

This review discusses the effects of hormonal treatments on the physical and mental health of transgender individuals, reporting significant reductions in mental health issues following treatment, but calls for more research on long-term and nonbinary outcomes.

This article suggests that modern lifestyle changes, including diet, stress, and chronic anti-inflammatory medication use, may disrupt the natural process of inflammation resolution, increasing vulnerability to chronic disease.

This study reported that treatment with gonadotropin-releasing hormone analogs and cross-sex hormones appears appropriate for carefully selected youth with gender dysphoria, but long-term safety needs further investigation.

This review suggests that understanding the biological and molecular reasons for more severe COVID-19 in men, particularly those at risk for prostate cancer, could improve management of these patients, but reports no new results.

This study classified dutasteride, fesoterodine, and finasteride as beneficial for older or frail elderly patients, while suggesting caution or avoidance of α-blockers and antimuscarinics in this group.

This review discusses current and emerging treatments for benign prostatic hyperplasia and emphasizes the need for further research to optimize treatment selection, but reports no new clinical results.

This article outlines the clinical features, evaluation, and treatment strategies for androgen excess in polycystic ovary syndrome, highlighting important diagnostic and management approaches but reporting no new research results.

Hair loss in androgenetic alopecia is caused by genetic factors and androgen excess, and can be treated with combined therapies.

This article reviews the effects of various medications on male fertility, noting that while commonly used drugs can mostly have reversible impacts, conclusive human evidence remains limited.

This review discusses various therapeutic agents for alopecia areata, categorized by efficacy and safety, and highlights the lack of curative treatments and long-term outcome studies.

This review offers transgender hormone treatment guidelines to assist healthcare providers in improving transgender patients' access to and outcomes of medical care, but it reports no new clinical results.

Some drugs can cause hair loss, and stopping these drugs often leads to hair regrowth.

This study suggests that CD8+ cytotoxic T lymphocytes play a crucial role in the development of alopecia areata, based on observations in rodent models that mimic human autoimmune disease.

This study found that despite the presence of steroidogenesis inhibitors, CRPC tumor cells adapt to continue synthesizing androgens, suggesting a need for more effective androgen axis targeting.

This review discusses possible medication-induced hair loss and the need to exclude other confounding factors like stress and illness; it reports no new clinical findings and emphasizes careful assessment before attributing hair loss to medications.

This review discusses various treatment recommendations for Chronic Prostatitis/Chronic Pelvic Pain Syndrome, noting the need for further trials on herbal therapies and specific indications for surgical intervention, but reports no new clinical results.